The highest drop is 93.61%!

On April 6, Hubei issued a notice on the results of the centralized procurement of 8 varieties including paroxetine oral regular-release dosage forms

The large variety of injections dropped by 93.

17 drugs have been suspended

The "Selected Varieties Supply Catalog" shows that among the 8 varieties, except for paroxetine tablets, which are still selected by Huahai, all the selected companies have been replaced, the original research companies have been wiped out, and the montelukast sodium tablets have been replaced by Merck and Jiangsu Wangao.

From the price point of view, compared with the expanded original selection (Hubei) price, the price dropped by an average of 49%

Due to the sharp price cuts of the newly selected varieties, Hubei also put forward new requirements for the non-selected varieties

At the same time, Hubei requires that if there are 3 or more manufacturers of similar drugs that have passed the consistency evaluation, the generic drugs that have not passed the consistency evaluation will be suspended; if there are not 3 (not included), the national provincial platform The lowest price of the currently implemented bid-winning/listed online price and the lowest price of the province's lowest online price for the same kind of drugs through the consistency evaluation are the upper limits, and the manufacturer independently declares the online price

It is also worth noting that Hubei did not directly abandon the original selected varieties.

Renewal rules or major changes

"Hubei model" attracts attention

Unlike the provinces that have successively issued contract renewal rules, Hubei has invited newly reviewed companies and unselected original research drug companies to participate in the bidding, and the lowest bidder is the newly selected company
.
Such new regulations have brought market opportunities for newly reviewed companies
.
However, this kind of contract renewal bidding has also brought further intensification of price competition
.

  The Hubei Medical Insurance Bureau stated that for some products with insufficient competition that expired in the state-organized purchase agreement, it introduced new over-evaluated products to bid for renewal, and found that the market was fully competitive with more reasonable prices
.
Through normalized centralized drug purchases, the province can save nearly 3 billion yuan in drug costs each year
.
In 2021, the Hubei Provincial Medical Insurance Bureau will actively explore and continue to promote the normalization and institutionalization of centralized drug procurement
.
Focus on including drugs with large amounts and high purchase amounts in the medical insurance catalog, and gradually cover all kinds of clinically necessary and reliable drugs on the market in China, so that all drugs should be collected
.

  According to industry sources, in the future, the state adopts the renewal rules or the provinces and autonomous regions will formulate them, and the competition rules will undergo major changes
.
Then, whether the new low price generated by Hubei's bid for renewal of centralized procurement will be linked across the country, and whether the Hubei model will form a trend, which has aroused the attention of the industry
.

  It is also worth noting that in the past two days, Shanghai also issued two notices on the third batch of state-organized centralized drug procurement and some drugs will no longer be included in the procurement restrictions and the fourth batch of state-organized centralized drug procurement.
The city’s unselected drugs will be adjusted in price.

.
The third batch of Shanghai’s national organization of centralized drug procurement has completed the agreed procurement volume of some drugs.
Starting from April 2, 2021, drugs that have been liquidated and have been voluntarily reduced to below the selected price before November 20, 2020 will no longer be included 1:1 purchase restriction
.
Shanghai also stated that the fourth batch of nationally organized drugs for centralized procurement of the city’s unselected original research drugs and generic drug companies that pass the consistency evaluation will not be regarded as "high-priced drugs" if they voluntarily reduce their prices below the city’s selected price (including the selected price).
, To increase the proportion of personal conceit
.
After the corresponding selected drug completes the agreed purchase quantity, the unselected drug will not be affected by the priority purchase restrictions and related assessments
.
In this regard, companies still need to accurately grasp local centralized procurement policies to find market opportunities
.